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TRPM1 Is Mutated in Patients with Autosomal-Recessive
Complete Congenital Stationary Night Blindness
Abstract
Night vision requires signaling from rod photoreceptors to adjacent bipolar cells in the retina. Mutations
in the genes NYX and GRM6, expressed in ON bipolar cells, lead to a disruption of the ON bipolar cell
response. This dysfunction is present in patients with complete X-linked and autosomal-recessive
congenital stationary night blindness (CSNB) and can be assessed by standard full-field
electroretinography (ERG), showing severely reduced rod b-wave amplitude and slightly altered cone
responses. Although many cases of complete CSNB (cCSNB) are caused by mutations in NYX and
GRM6, in ~60% of the patients the gene defect remains unknown. Animal models of human diseases
are a good source for candidate genes, and we noted that a cCSNB phenotype present in homozygous
Appaloosa horses is associated with downregulation of TRPM1. TRPM1, belonging to the family of
transient receptor potential channels, is expressed in ON bipolar cells and therefore qualifies as an
excellent candidate. Indeed, mutation analysis of 38 patients with CSNB identified ten unrelated cCSNB
patients with 14 different mutations in this gene. The mutation spectrum comprises missense, splice-site,
deletion, and nonsense mutations.We propose that the cCSNB phenotype in these patients is due to the
absence of functional TRPM1 in retinal ON bipolar cells.
TRPM1 is mutated in patients with complete autosomal recessive congenital 
stationary night blindness 
Running Title: Mutations in TRPM1 cause complete arCSNB 
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SUMMARY 
Night vision requires signaling from rod photoreceptors to adjacent bipolar cells in the 
retina. Mutations in the genes NYX and GRM6, expressed in ON-bipolar cells, lead to 
a disruption of the ON-bipolar response. This dysfunction is present in patients with 
complete X-linked and autosomal recessive (ar) congenital stationary night blindness 
(CSNB) and can be assessed by standard full-field electroretinography (ERG), 
showing severely reduced rod b-wave amplitude and slightly altered cone responses. 
Although many cases of complete (c)CSNB have been caused by mutations in NYX 
and GRM6, in ~60% of the patients the gene defect remains unknown. Animal models 
of human diseases are a good source for candidate genes, and we noted that a cCSNB 
phenotype present in homozygous Appaloosa horses is associated with down-
regulation of TRPM1. TRPM1, belonging to the family of transient receptor potential 
channels, is expressed in ON-bipolar cells and therefore qualifies as an excellent 
candidate. Indeed, mutation analysis of 38 patients with CSNB identified 10 unrelated 
cCSNB patients with 14 different mutations in this gene. The mutation spectrum 
comprises missense, splice site, deletion and nonsense mutations. We propose that the 
cCSNB phenotype in these patients is due to the absence of functional TRPM1 in 
retinal ON-bipolar cells.  
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Congenital stationary night blindness (CSNB) is a group of genetically and clinically 
heterogeneous retinal disorders. The genes involved in the different forms of CSNB 
encode proteins, which are confined to the phototransduction cascade or are important 
in retinal signaling from photoreceptors to adjacent bipolar cells 1. Most of the 
patients with mutations in these genes show a typical electrophysiological phenotype 
characterized by an electronegative waveform of the dark-adapted bright flash 
electroretinogram (ERG), in which the amplitude of the b-wave is smaller than that of 
the a-wave 2. This so-called Schubert-Bornschein type ERG response can be divided 
in two subtypes, incomplete (ic)CSNB (CSNB2A [MIM 300071], CSNB2B [MIM 
610427]) and complete (c)CSNB (CSNB1A [MIM 310500], CSNB1B [MIM 257270] 
3. The incomplete type is characterized by both a reduced rod b-wave and 
substantially reduced cone response, due to both ON- and OFF-bipolar dysfunction, 
while the complete type is associated with a drastically reduced rod b-wave response, 
but largely normal cone b-wave amplitudes due to ON-bipolar dysfunction 4.  
In a considerable fraction of CSNB patients mutations have been identified by direct 
sequencing of candidate genes or microarray analysis 5. However, from our CSNB 
cohort the phenotype in ~60% of the patients could not be associated with mutations 
in known genes, indicating that additional genes remain to be identified. Recently, a 
type of CSNB in Appaloosa horses has been described 6; 7. Affected animals initially 
showed reduced vision in dim light, which subsequently progressed to reduced vision 
even in normal light conditions in severely affected animals. No fundus abnormalities 
were present, but strabismus and nystagmus were described. Electrophysiological 
studies revealed a “negative ERG” resembling the human Schubert-Bornschein type 
CSNB 8. Furthermore, the photopic flicker responses of affected horses seemed to be 
similar when compared with unaffected horses 6 suggesting a phenotype reminiscent 
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of complete CSNB. Association studies of the coat coloring in these horses revealed 
that this trait is directly linked with the CSNB phenotype. Gene expression analysis of 
genes linked to this disorder revealed that TRPM1 (MIM 603576), also known as 
Melastatin (MLSN1) was significantly down-regulated in the retina and skin of 
affected animals. Thus it was proposed that TRPM1 is responsible for altering bipolar 
signaling as well as melanocyte function causing both CSNB and the coat color 
phenotype in Appaloosa horses 9. Studies in mice lacking Trpm1 revealed a severely 
reduced b-wave in ERG recordings similar to the Schubert-Bornschein type ERG 
response 10. These findings support the hypothesis that this gene is indeed important 
for night vision.  
TRPM1 is a member of the transient receptor potential (TRP) channel family. These 
channels permit Ca2+ entry into hyperpolarized cells, producing intracellular 
responses linked to the phosphatidylinositol and protein kinase C signal transduction 
pathway 11. Due to the down-regulation of TRPM1 in Appaloosa horses with CSNB, it 
was suggested that this gene may play a role in neural transmission in the human 
retina through changing cytosolic-free Ca2+ levels in the retina in ON-bipolar cells. 
The mGluR6 protein (MIM 604096) of the ON-bipolar cells is coupled to Gαo (MIM 
139311) proteins and to TRPM1. TRPM1 might be the cation channel that is 
downstream of the Gαo protein in the ON-bipolar cells 9.  
 
Altogether, the phenotype of Appaloosa horses, the down-regulation of TRPM1 in 
affected animals and its localization downstream of mGluR6 in ON-bipolar cells 
rendered this gene a good candidate. Thus we screened this gene in 38 clinically 
diagnosed CSNB patients from different centers in Europe and the United States 
(Belgium: Ghent, France: Paris, Montpellier and Lille, Germany: Berlin, Freiburg, 
 5
Giessen and Tuebingen, Switzerland: Lausanne, United States: Philadelphia, PA). 
Prior to this study, most patients were excluded either for known mutations using a 
CSNB genotyping microarray, or for known CSNB genes and additional candidate 
genes by direct sequencing 5. Research procedures were conducted in accordance with 
institutional guidelines and the Declaration of Helsinki. Prior to genetic testing, 
informed consent was obtained from all patients and their family members. 
Ophthalmic examination included best corrected visual acuity, slit lamp examination, 
funduscopy, Goldmann kinetic perimetry, full-field electroretinography (ERG) 
incorporating the ISCEV standards 12, fundus autofluorescence and optical coherence 
tomography (OCT) (extent of investigation depending on the referring center). Thirty 
fragments covering 27 exons of TRPM1 (RefSeq NM_002420.4, 70+TRPM1), two 
fragments corresponding to two recently identified exons, exon 1’ (92+TRPM1) and 
exon 0 (109+TRPM1) of this gene 13 (Figure 1), and the flanking intronic regions 
were directly sequenced from the PCR amplified products (primers: Supplementary 
Table 1) with the use of a sequencing mix (BigDyeTerm v1.1 CycleSeq kit, Applied 
Biosystems, Courtabœuf, France), analyzed on an automated 48-capillary sequencer 
(ABI 3730 Genetic analyzer, Applied Biosystems) and the results interpreted by 
applying a software (SeqScape, Applied Biosystems).  
Analysis in TRPM1 revealed causative mutations in 10 cCSNB patients (Figure 2, 
patient CIC00238 as an example of cCSNB) with a total of 14 different mutations 
(Table 1, Figure 1). These comprise nonsense mutations, a deletion leading to a 
predicted premature stop codon, splice site, silent and missense mutations. None of 
these changes were found among control chromosomes (210-380 chromosomes). In 
those patients from whom family members could be investigated, the cCSNB 
phenotype co-segregated with the mutations and the genotypes were indicative for 
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autosomal recessive inheritance (Figure 3A and B: 3 examples). Five index patients 
showed compound heterozygous mutations (Table 1, 4497, 8214, CIC00612, 23625 
and 758). Patients CIC00612, 23625 revealed both a heterozygous p.Tyr72Cys 
substitution. From the origins of these patients, no close familial relationship was 
obvious. In three index patients an apparently homozygous mutation was found 
(Table 1, CIC00238, 691 and D0704708). Homozygosity was proven for index patient 
D0704708 (Figure 3). Co-segregation analysis from family members of index patient 
CIC00238 revealed that another affected sister was apparently homozygous for the 
mutation, while the father was heterozygous. Two unaffected sisters and interestingly 
the mother did not show the mutation (Table 1). These findings indicated that the 
patient is most likely heterozygous for the missense mutation inherited from the father 
and, in addition would have a deletion in TRPM1 or a mutation in another gene, 
which would have been inherited from the mother. Four investigated SNPs 
(rs4779818 in intron1, rs4779816 in exon 2, rs2241493 in exon 3 and rs2288242 in 
exon 18) were apparently homozygous in the patient and parents and thus the putative 
deletion could not be defined. Analyses of additional SNPs in genomic regions of 
TRPM1 or screening of candidate genes may enable us to localize the second 
mutation and will be investigated in the future. The parents of 691 were not available 
for genetic testing and thus homozygosity could not be proven. For two patients, 
14101 and 10731 only one heterozygous mutation was identified (Table 1). Again the 
second mutation may be a large heterozygous deletion and thus not detectable by 
PCR-based sequencing. In addition, a mutation located in a second gene may disable 
signaling important for nocturnal vision. Three investigated SNPs (rs4779816 in exon 
2, rs2241493 in exon 3 and rs3782599 in exon 4) were apparently homozygous in the 
patient and parents, and thus the putative deletion could not be defined. Mutation 
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analysis in patient 14101 on other known or candidate genes (NYX, AJ278865 
[300278]; GRM6, NM_000843; CABP4, NM_145200 [MIM 608965]; CACNA2D4, 
NM_172364 [MIM 608965]; BHLHB4, BK000274 [MIM 609331]; CACN2B, 
NM_000724 [MIM600003]; GNA01, NM_020988 and NM_138736 and TBC1D2, 
NM_018421 [MIM609871]) did not reveal any mutation. Previous mutation analyses 
in the simplex case 10731 in known and candidate genes (NYX, CACNA1F, AJ006216 
[MIM 300110], GRM6; CABP4, CACNA2D4, BHLHB4, CACN2B, GNA01 and 
TBC1D2) did not reveal any mutation. Thus for both patients the second mutation 
may be found in other regions of TRPM1 such as regulatory sequences or unidentified 
exons or may represent a deletion in an as-yet uninvestigated region of TRPM1. 
Alternatively, the second mutation may be found in a novel CSNB gene.  
One other patient, 13830 with icCSNB was compound heterozygous for two missense 
changes: c.1195C>A, causing a p.Pro399Thr substitution in exon 10, and c3483G>C, 
leading to a p.Gln1161His substitution in exon 26, respectively (Table 2). However 
the c.1195C>A was found in 8 of 350 and the c.3483G>C in 2 of 266 control 
chromosomes. Thus both variants are most likely non-disease causing variants. This is 
also consistent with the fact that TRPM1 mutations in our study specifically lead to 
complete and not incomplete CSNB. Another variant (c.4123G>T) in exon 27 leading 
to a p.Glu1375X, was detected in three patients but turned out to be a SNP 
(rs378489), which was detected in 20 of 320 control chromosomes. Other presumably 
non-disease causing variants were detected and are summarized in Table 3. 
 
The most likely pathogenic mutations identified herein were predicted to localize at 
different sites of the transient receptor potential channel. Five missense mutations, 
which were found in evolutionary conserved residues (Figure 4), one silent and one 
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nonsense mutation were predicted to localize in the N-terminal intracellular part of 
TRPM1 (Figure 5), the function of which is yet not understood. 11 All missense 
mutations where predicted by homology-based programs (SIFT amd Polyphen, data 
not shown) to be pathogenic. Another silent mutation was identified in the C-terminus 
of TRPM1. For all of these, in addition to the splice site mutations, splicing could be 
influenced since different splicing proteins were predicted to bind to the mutated 
variants compared to control (Web-based ESEfinder, data not shown). In addition, 
mislocalization of the mutated proteins or channel gating defects could be the 
underlying pathogenic mechanisms leading to cCSNB. In total five different 
mutations predicted to lead to premature termination codons in different locations of 
the protein, were identified. We assume that the corresponding mutant mRNAs of 
these alleles would likely be subjected to nonsense mediated decay or produce a short 
non-functional form of TRPM1. Previous studies showed that a shorter, alternatively 
spliced N-terminal form devoid of any putative transmembrane segments (amino 
acids ~1-500) of TRPM1 can directly interact and suppress the activity of the full-
length form by preventing its translocation to the plasma membrane, and thus 
inhibiting Ca2+ entry into the cell 14. It was suggested that under normal conditions 
this mechanism regulates the exact amount of molecules necessary for proper channel 
function.  
 
Currently there are two genes NYX and GRM6 implicated in complete CSNB 15-18. 
They code for the proteins nyctalopin and mGluR6, respectively, which localize 
postsynaptically to the photoreceptors in the retina in ON-bipolar cells 19. While the 
function of nyctalopin is not yet understood, mGluR6 was shown to be important for 
the glutamate uptake released from the photoreceptors (Figure 6). The most obvious 
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phenotypical feature of patients with cCSNB is a defect of the ON-response resulting 
in an electronegative combined rod-cone ERG, based on a severely reduced b-wave 2. 
In the dark, glutamate is released from photoreceptors, binds to mGluR6 and activates 
the Gαo1 subunit of a heterotrimeric G-protein. This in turn leads by an unidentified 
mechanism to the closure of a so far unknown cation channel (Figure 6) 1; 20-25Upon 
light exposure, photoreceptor glutamate release decreases and the ON-response is 
initiated with the shutting down of the G-protein cascade. Subsequently, the cation 
channel opens leading to ON-bipolar cell depolarization, giving rise to the b-wave. 
Mutations in GRM6 lead to the loss of mGluR6 at the cell surface. Modulation of 
glutamate released from the photoreceptors cannot be correctly sensed by the bipolar 
cells, resulting in the failure of depolarization and thus a severely reduced b-wave 26. 
Recent findings in Appaloosa horses with CSNB and a specific coat patterning caused 
by low expression of a TRP channel, Trpm1, suggested that this specific channel is 
specifically linked to the depolarization of the ON-bipolar cells during light exposure. 
However, no direct sequencing of the Trpm1 gene in the horse was performed and 
thus the loss of ON-bipolar cell function could rather be due to a secondary effect 
than due to the mutated Trpm1. Nevertheless mice lacking this channel showed the 
same ocular phenotype with a severely reduced b-wave 10. Together these findings 
indicated that mutations in this gene could be responsible for CSNB in patients, and 
indeed our study presented herein revealed 14 different mutations in TRPM1 in 10 
different families with complete autosomal recessive CSNB. 
Patients carrying mutations in TRPM1 reveal a similar ocular phenotype. All showed 
complete congenital stationary night blindness with selective dysfunction of the ON-
bipolar pathway and OFF-bipolar pathway preservation. Most of them revealed at 
least one of the following additional ocular abnormalities: myopia, nystagmus and 
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strabismus. These clinical observations are in accordance with the phenotype 
observed in the night blind Appaloosa horses also showing nystagmus and strabismus. 
Although Bellone and co-workers showed down-regulation of Trpm1 in these horses, 
it will be interesting to see which mutations in Trpm1 lead to its down-regulation. Due 
to the fact that the ocular phenotype was similar in all patients and the presence of a 
large fraction of nonsense and splice site mutations, we hypothesize that this form of 
complete arCSNB is due to a lack of TRPM1 mRNA or functional TRPM1 protein on 
the surface, rather than due to functional alterations in the biophysical properties of 
this channel. Animal models carrying the identified mutations and investigation of 
transcript in the retina are needed to verify this hypothesis.  
 
To date three genes have been associated with icCSNB (CACNA1F, CABP4 and 
CACNA2D4) 27-30 and now with the findings reported here there are also three genes 
associated with cCSNB (NYX, GRM6, TRPM1)15-18 (Figure 7). In respect to the other 
arCSNB genes identified so far, TRPM1 seems to be the most frequently mutated 
gene.  
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APPENDICES 
Databases used to predict the pathogenic character of a sequence alteration 
1. National Center for Biotechnology Information (NCBI) http://ncbi.nlm.nih.gov/ 
2. Online Mendelian Inheritance in Man http://ncbi.nlm.nih.gov//Omim 
3. USCS Human Genome Browser http://genome.ucsc.edu/ 
4. GenCards, PolyPhen (Polymorphism Phenotyping, http://tux.embl-
heidelberg.de/ramensky/) 
5. SIFT (Sorting Intolerant From Tolerant, http://blocks.fhcrc.org/sift/SIFT.html) 
6. UniProtKB/Swiss-Prot, www.uniprot.org 
7. ESEfinder, http://rulai.csh2.edu/tools/ESE 
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FIGURE LEGENDS: 
 
Figure 1: TRPM1 isoforms and CSNB mutations. 
The 70+TRPM1 gene structure represents the previously published reference 
sequence (RefSeq NM_002420.4), while the 92+TRPM1 and 109+TRPM1 isoforms 
were only recently identified 13. Compared to 70+TRPM1 the 92+TRPM1 contains 22 
and the 109+TRPM1 isoform 39 additional amino acids. The new ORF of 
92+TRPM1 is made of the complete exon 2 with the initiation codon located in a new 
exon (exon 1’). The new ORF of 109+TRPM1 is made of the complete exon 2 and a 
new exon (exon 0). Both new ORFs continue in the isoform 70+TRPM1 coding for 
1625 and 1642 amino acids respectively.  
 
Figure 2: Electrophysiologic description of patient CIC00238 with complete CSNB as 
an example: full-field ERGs show typical ON-bipolar pathway dysfunction: there are 
no detectable responses for the dark-adapted 0.01 ERG; dark-adapted 3.00 and 12.0 
ERGs show an a-wave with a normal amplitude and implicit time but a severely 
reduced b-wave leading to an electronegative waveform. Dark-adapted oscillatory 
potentials are not detectable. Light-adapted 3.0 ERGs show normal amplitudes but 
implicit time shift for both the a- and b-wave. The a-wave has a broadened trough and 
there is a sharply arising b-wave with no oscillatory potentials (OPS). Light-adapted 
3.0 Flicker ERGs show normal amplitudes but a broadened trough and a mildly 
delayed implicit time. These photopic ERG appearances are characteristic of selective 
dysfunction of the ON-bipolar pathway with OFF-bipolar pathway preservation 31. 
This is further confirmed with long duration stimulations, which reveal a normal a-
wave but severely reduced ON-response b-wave and a preserved OFF-response d-
wave. 
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 Figure 3: TRPM1 mutations and co-segregation analysis in families with CSNB. 
(A) Electropherograms of three index patients as an example showing TRPM1 
mutations, which are highlighted by an arrow. (B) Corresponding pedigrees of 
selected complete CSNB patients with TRPM1 mutations and co-segregation in 
available family members. Filled symbols represent affected and unfilled unaffected 
persons. Squares indicate males, circles females. Arrows reflect the index patients.  
 
Figure 4: Evolutionary conservation of the altered amino acid residues in other 
orthologs. Multiple amino acid sequence alignments show evolutionary conservation 
of mutated residues (depicted in green). Amino acid substitutions are highlighted in 
red. The position of the respective amino acids is shown in black numbers. 
 
Figure 5: Localization of TRPM1 mutations with respect to predicted channel 
domains. The specific domains for the TRPM1 channel were estimated by using 
different publications and prediction programs 14; 32 (UniProtKB/Swiss-Prot, 
www.uniprot.org). 
 
Figure 6: Schematic drawing of proteins involved in signal transmission from 
photoreceptors to adjacent bipolar cells, the disruption of which lead to CSNB. 
Arrows indicate the course of the signal transmission. In darkness, Ca2+ ions enter the 
rod photoreceptors, which results in glutamate release from the photoreceptors. 
Activated glutamate receptor activates Gαo1 (arrow), which then closes the TRPM1 
channel by an unknown mechanism, indicated by a question mark, and thus ON-
bipolar cells are hyperpolarized. The exact role of NYX, encoding nyctalopin in this 
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signal transduction cascade remains to be solved in the future (indicated by a question 
mark). 
 
Figure 7: Genes underlying CSNB. Different forms of human CSNB are classified 
according to their mode of inheritance, the phenotype and mutated genes. 
Abbreviations: cCSNB = complete CSNB; icCSNB =incomplete CSNB; ar = 
autosomal recessive, ad = autosomal dominant. Genes are indicated in italics and 
underlined. Chromosomal location is given between brackets. The phenotype of 
patients with mutations in icCSNB is more variable and can even lead to progressive 
cone or cone-rod dystrophy 1.
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